10 Best New Stocks to Buy With Huge Upside Potential
Ed Yardeni of Yarden Research told CNBC’s “Squawk Box” that a June “swoon” after stronger-than-expected payrolls may have been limited to June 5, and he expects further upside in July. He cited SpaceX’s IPO as a positive sentiment signal and said S&P 500 firms are projected to grow earnings ~20% over seven quarters. The article also lists new stocks with claimed upside, including Caris Life Sciences’ $100m buyback authorization and Atour’s Q1 2026 revenue of RMB2.8b (+47.5% YoY).
How this was made
The 30-second read
Why it matters
For CAI and ATAT, the actionable content is limited to previously disclosed board authorization (CAI) and reported quarterly results (ATAT). The rest is macro/market commentary that does not introduce new, company-specific catalysts.
Market read
Traders get a recap of two company-specific datapoints (buyback authorization; quarterly growth/expansion), but the article does not provide fresh guidance, filings, or same-day catalysts.
What to watch
For CAI, execution details (timing/price) and any concurrent financing needs matter; for ATAT, RevPAR/occupancy and margin sustainability are key, and the article omits guidance/forward commentary.
Background
The piece is a promotional “10 best new stocks” list, anchored by an interview with Ed Yardeni on market momentum and earnings strength.
Ticker impact
Caris Life Sciences authorized a $100M share repurchase program on June 8, giving a concrete capital-return catalyst for CAI.
Near-term bias modestly positive; follow-through depends on execution pace and stock reaction to the June 8 authorization.
The article discloses a specific board-authorized repurchase size and mechanics, which traders can map to potential support, though it’s not a guidance/earnings surprise.
Atour Lifestyle reported Q1 2026 results with revenue up 47.5% YoY and EBITDA growth, plus continued hotel expansion.
Potentially positive near-term sentiment; magnitude depends on how the market interprets profitability and unit economics.
The article provides multiple hard financial/operational datapoints from the quarter, but it’s framed as a listicle rather than a fresh same-day catalyst.
Market effects
Highlights capital-return (buybacks) and growth/expansion narratives in healthcare/precision medicine and hospitality, but without sector-wide new data.
ATAT’s results are China-exposed; sentiment could be influenced by broader China consumer/hospitality demand expectations, though no new macro datapoint is provided.
Mentions SpaceX/AI sentiment broadly, but provides no direct global market mechanism tied to CAI or ATAT.
Counterpoint
Listicle framing may overstate “huge upside”; buyback authorization and prior-quarter results may already be priced, limiting incremental edge.
Key entities
- companyCaris Life Sciences Inc.
Board authorized up to $100M common stock repurchases (June 8).
- companyAtour Lifestyle Holdings Limited
Reported Q1 2026 results with revenue and profitability growth and continued hotel expansion (reported May 13).
- personEd Yardeni
Yarden Research president quoted on market momentum and earnings-led upside.
